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Introduction: Subcortical hyperintensities (SHs) are radiological entities commonly observed on magnetic resonance
imaging (MRI) of patients with Alzheimer’s disease (AD) and normal elderly controls. Although the presence of SH is
believed to indicate some form of subcortical vasculopathy, pathological heterogeneity, methodological differences,
and the contribution of brain atrophy associated with AD pathology have yielded inconsistent results in the literature.
Methods: Using the Lesion Explorer (LE) MRI processing pipeline for SH quantification and brain atrophy, this
study examined SH volumes of interest and cognitive function in a sample of patients with AD (n = 265) and normal
elderly controls (n = 100) from the Sunnybrook Dementia Study.
Results: Compared with healthy controls, patients with AD were found to have less gray matter, less white matter, and
more sulcal and ventricular cerebrospinal fluid (all significant, P <0.0001). Additionally, patients with AD had greater
volumes of whole-brain SH (P <0.01), periventricular SH (pvSH) (P <0.01), deep white SH (dwSH) (P <0.05), and lacunar
lesions (P <0.0001). In patients with AD, regression analyses revealed a significant association between global atrophy
and pvSH (P = 0.02) and ventricular atrophy with whole-brain SH (P <0.0001). Regional volumes of interest revealed
significant correlations with medial middle frontal SH volume and executive function (P <0.001) in normal controls but
not in patients with AD, global pvSH volume and mental processing speed (P <0.01) in patients with AD, and left
temporal SH volume and memory (P <0.01) in patients with AD.
Conclusions: These brain-behavior relationships and correlations with brain atrophy suggest that subtle, yet
measurable, signs of small vessel disease may have potential clinical relevance as targets for treatment in
Alzheimer’s dementia.Introduction
Subcortical hyperintensities (SHs) are commonly observed
radiological entities on T2-weighted (T2), proton density
(PD), and fluid attenuated inversion recovery (FLAIR)
magnetic resonance images (MRIs) of the aging brain
[1,2]. Often referred to as leukoaraiosis, these diffuse white* Correspondence: joelr@sri.utoronto.ca
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unless otherwise stated.matter (WM) abnormalities appear as hyperintense bright
spots on PD/T2 MRIs and are believed to reflect
some form of small vessel disease [3-5]. Although the
pathological origins of SH and their contribution to the
expression of dementia remain controversial, recent
studies have shown SH to be associated with cognitive
function, gait disturbances, and mental processing speed
[6-13].
SH can be subclassified as periventricular (pvSH) and
deep white (dwSH) [14-16]. Additionally, cystic lacunar
infarcts can be measured if T1-weighted (T1) acquisitionsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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algorithms typically include MRI-derived volumetric esti-
mates for gray matter (GM), WM, sulcal cerebrospinal
fluid (sCSF), and ventricular CSF (vCSF). However, since
T1-based segmentations may result in misclassified tissue
volumetrics due to the relative intensity of SH on T1 [17],
an additional PD/T2/FLAIR-based SH segmentation is
recommended to correct for this error and account for
the possible contribution of ischemic vascular injury, par-
ticularly with studies examining aging and dementia [19].
The purpose of the present study is to better under-
stand the complex relationships between MRI measures
of small vessel disease, atrophy, and cognition in patients
with sporadic Alzheimer’s disease (AD) and cognitively
normal elderly controls (NCs). More specifically, this study
used MRI-derived (T1/T2/PD) volumetrics to determine
whether regional SH volumes of interest (VOIs) were
differentially correlated with atrophy and performance




MRI scans were obtained on patients with AD (AD:
n = 265) and cognitively normal elderly volunteers (NC:
n = 100) enrolled in the Sunnybrook Dementia Study
(ClinicalTrials.gov: NCT01800214), which is a large on-
going longitudinal study conducted in the LC Campbell
Cognitive Neurology Research Unit and the Heart &
Stroke Foundation Canadian Partnership for Stroke
Recovery, at Sunnybrook Health Sciences Centre in
Toronto, Canada.
Patients with AD were slightly older (AD = 72.8 ± 9.0
versus NC = 69.5 ± 8.0, P <0.001) and less educated
(AD = 13.8 ± 3.8 versus NC = 15.5 ± 3.0, P <0.001). The
presence/non-presence of SH was not an exclusionary
criterion for this study, and both groups showed a
non-normal distribution of SH volumes. Participants
were excluded if they had signs of Parkinson’s disease
or neurological diseases other than dementia, history
of significant head trauma, psychotic disorders unrelated
to dementia, psychoactive substance abuse, major de-
pression, and other clinically significant pathology such as
overt stroke, tumors, or normal pressure hydrocephalus.
Patients with AD met National Institute of Neurological
and Communicative Disorders and Stroke (NINCDS)
Alzheimer’s Disease and Related Disorders Association
(ADRDA) criteria for probable or possible AD [20] and
Diagnostic and Statistical Manual of Mental Disorders
(4th ed.) [21] criteria for dementia. All patients received a
standardized comprehensive clinical evaluation. NC par-
ticipants were community-dwelling with no subjective or
objective cognitive impairment and no history of signifi-
cant psychiatric or neurological diseases. All NC met strictcriteria, including pre-screening followed by a battery of
neuropsychological testing with performance threshold
requirements for consideration. The study protocol was
approved by the Sunnybrook Research Ethics Board (REB
PIN no. 009-1998), and written informed consent was ob-
tained from all participants or their caregivers/decision-
makers or both.
Neuropsychological tests
Neuropsychological testing was performed within 12 weeks
of MRI acquisition and administered according to standard
protocols. Executive function, mental processing speed,
and memory domain tests were selected because these
domains have been most consistently associated with SH
in the previous literature. (See Table 1 for specific measures
used.) Executive function was assessed by using perform-
ance scores obtained from the F-A-S phonemic verbal flu-
ency task [22] and the Wisconsin Card Sorting Test [23].
The time to complete the Trails A trail-making test was
used to assess speed of mental processing [24]. The
California Verbal Learning Test [25], Wechsler Memory
Scale-Revised immediate Visual Reproduction [26], and
the Dementia Rating Scale memory subscore [27] were
used to assess memory. Composite scores were generated
by using normalized mean z-scores and normal elderly
control population data from the Sunnybrook Dementia
Study.
MRI acquisition protocols
All brain imaging data were obtained on a 1.5 Tesla GE
Signa (Milwaukee, WI, USA) system in compliance with
consensus recommendations for studies examining vascu-
lar cognitive impairment [19]. Three image sets were used:
a T1-weighted—axial three-dimensional (3D) Spoiled
Gradient Recalled Echo (SPGR): 5 ms echo time (TE),
35 ms repetition time (TR), 1 number of excitations
(NEX), 35° flip angle, 22 × 16.5 cm (FOV), 0.859 ×
0.859 mm in-plane resolution, 1.2 to 1.4 mm slice thickness
depending on head size—and an interleaved PD and T2
(interleaved axial dual-echo spin echo: TEs of 30 and
80 ms, 3 s TR, 0.5 NEX, 20 × 20 cm FOV, 0.781 ×
0.781 mm in-plane resolution, 3 mm slice thickness).
MRI processing
Full methodological details and reliability results of the
image processing pipeline are previously published
[18,28]. In brief, the Lesion Explorer (LE) processing
pipeline (available for download at sabre.brainlab.ca), a
tri-feature (T1/PD/T2) segmentation and parcellation
procedure, was applied to obtain regionalized and whole-
brain volumetrics for GM, WM, sCSF, vCSF, periventricu-
lar SH (pvSH), deep white SH (dwSH), and cystic fluid
filled lacunar-like infarcts (lacunes). The Brain-Sizer com-
ponent of LE effectively removed skull and other non-
Table 1 Summary of cognitive domains and measures used to generate composite scores
Domain Test Measure
Executive
Verbal Fluency ‘FAS’ Test Total words correct
Wisconsin Card Sorting Test Total correct
Wisconsin Card Sorting Test Perseverative errors to previous response
Wisconsin Card Sorting Test Perseverative errors to previous category
Mental processing speed Trail Making Test (part A) Time to complete (seconds)
Memory
California Verbal Learning Test Total correct at acquisition
Wechsler Memory Scale Revised Visual Reproduction Immediate recall
Dementia Rating Scale Memory subscore
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tentorial total intracranial volume (ST-TIV), a process
which included a measure of subarachnoid CSF immedi-
ately below the dura mater. A robust T1-based basic tissue
(GM, WM, sCSF) segmentation, which fits localized voxel
intensities to four Gaussian curves, was performed [29].
The Semi-Automatic Brain Region Extraction (SABRE)
component of LE parcellated the brain into 26 stan-
dardized VOIs described in a previous publication [30].
The third component of LE segmented SH from PD/T2,
parcellated each volume into the 26 SABRE VOIs, sepa-
rated SH volumes into pvSH and dwSH by using a 3D
connectivity algorithm, and further segmented lacunar-
like infarcts within each SH volume by using information
from the initial T1 segmentation. The final output pro-
vided a comprehensive volumetric profile for each individ-
ual that included volumetrics within 26 SABRE VOIs for
GM, WM, sCSF, vCSF, pvSH, dwSH, and lacunes.
Terminology and definitions were in compliance with
the international neuroimaging standards recently rec-
ommended by the STandards for ReportIng Vascular
changes on nEuroimaging (STRIVE) [2].
Statistical analyses
Although mean raw volumetric data are presented for
transparency purposes and volumetric comparisons
across studies (Table 2), all statistical analyses were
performed on normalized values following a previously
published standard procedure [31] and subsequently
converted to z-scores (with log transformation when
required). Between-group volumetric differences (AD
versus NC) were compared by using analysis of covariance
(ANCOVA). Cohen’s d effect sizes were calculated for
significant between-group comparison results by using the
pooled standard deviation method on corrected data
(note: volumetric tables show raw data). A standardized a
priori VOI-based analysis approach was used to test the
SABRE VOIs. In brief, step-wise modeling for exploratory
analyses combined the SABRE VOIs for each of the four
major lobes (frontal, parietal, temporal, and occipital)
which yielded reasonable associations for our VOIs. Afterlocalizing the correlations to a particular lobe, subregional
parcellations within each SABRE subregion were entered
into the a priori subparcels into each regression model,
which was limited to a maximum of six VOIs per model.
Within-group SH VOI correlations with cognitive perfor-
mance scores were assessed by using linear regression
with backwards elimination of non-significant variables.
All analyses accounted for age, sex, years of education,
and brain parenchymal fraction (BPF), where BPF was
defined as a measure of whole-brain atrophy, calculated
by dividing the total parenchymal volume (GM+WM) by
the ST-TIV. After removal of the cerebellum and subten-
torial structures, ST-TIV was calculated for each individ-
ual and included all parenchyma (GM+WM), SH and
lacunar volumes, sulcal and ventricular CSF, and all CSF
immediately below the dura mater to provide an accurate
measure of the intracranial cavity. In addition to BPF, head
size-corrected vCSF volumes (vCSF/ST-TIV) were ana-
lyzed as another commonly used imaging biomarker of
brain atrophy [32-34]. Age, sex, years of education, and
scores from the Mini-Mental State Exam (MMSE) [35]
were entered as covariates to account for differences in
disease severity.
Results
Demographic and volumetric results are presented in
Table 2. ST-TIV was not significantly different and was
comparable to those reported in the literature (P = 0.20,
n.s.). Compared with NC, patients with AD were found
to have less overall brain matter (smaller BPF%), less
GM, less WM, and more sCSF and vCSF (all significant,
P <0.0001), and relatively large effect sizes were demon-
strated for overall brain atrophy and all basic tissue type
comparisons (BPF%: d = 1.35, GM: d = 1.35, WM: d = 0.92,
sCSF: d = 1.24, vCSF: d = 1.01). In addition, patients with
AD had greater volumes of whole-brain SH (p <0.01),
pvSH (P <0.01), dwSH (P <0.05), and lacunes (P <0.0001),
and a medium effect size was demonstrated for whole-
brain SH, pvSH, and lacunar volumes (SH: d = 0.54, pvSH:
d = 0.51, lacunes: d = 0.58), and a smaller effect size for
dwSH (d = 0.38).
Table 2 Participant demographics and volumetric imaging statistics
AD NC P value Cohen’s d effect size
Demographics
Number 265 100 - -
Age, years 72.8 (9.0) 69.5 (8.0) <0.001 0.38
Sex, number (percentage) female 152 (57) 55 (55) - -
Education, years 13.8 (3.8) 15.5 (3.0) <0.001 0.47
MMSE/30a 23.2 (4.5) 29.0 (1.1) <0.05 1.49
Basic tissue volumetricsb
ST-TIV 1,211.8 (140.1) 1,227.7 (112.5) n.s. -
BPF% 73.1 (4.6) 79.0 (3.7) <0.0001 1.35
GM 509.9 (55.7) 560.8 (45.0) <0.0001 1.35
WM 363.6 (55.1) 403.1 (52.3) <0.0001 0.92
sCSF 274.8 (62.5) 224.2 (48.1) <0.0001 1.24
vCSF 52.9 (27.1) 34.1 (16.2) <0.0001 1.01
SH volumetrics
SH, median (IQR) 5.4 (11.0) 2.5 (3.3) <0.01 0.54
pvSH, median (IQR) 4.5 (9.9) 1.8 (3.0) <0.01 0.51
dwSH, median (IQR) 0.6 (1.1) 0.3 (0.6) <0.05 0.38
Lacunar, mm3, median (IQR) 32.8 (155.9) 10.3 (45.0) <0.0001 0.58
Values reported are mean (standard deviation) unless otherwise specified. aAvailable in 97 cognitively normal elderly controls (NC) and 258 Alzheimer’s disease (AD)
subjects. bAll volumes expressed in cubic centimeters unless otherwise indicated. BPF, brain parenchymal fraction; dwSH, deep white subcortical hyperintensity; GM,
gray matter; IQR, interquartile range; MMSE, Mini-Mental State Exam; n.s., not significant; pvSH, periventricular subcortical hyperintensity; sCSF, sulcal cerebrospinal fluid;
SH, subcortical hyperintensity; ST-TIV, supratentorial total intracranial volume; vCSF, ventricular cerebrospinal fluid; WM, white matter.
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cognitive performance scores are summarized in Table 3.
In AD, regression analyses revealed a significant correl-
ation with atrophy measured by BPF and pvSH volume
(β = −0.14, R2 = 0.02, P = 0.02) and atrophy measured
by vCSF and total SH (β = 0.31, R2 = 0.10, P <0.0001)
(Figure 1). Medial middle frontal (MMF) SH volumes
were significantly correlated with executive function
in NC (β = −0.24, R2 = 0.07, P = 0.01) but not in AD
(Figure 2). Mental processing speed was significantly
correlated with pvSH volume in AD (β = 0.17, R2 = 0.03,
P = 0.01) but not in NC (Figure 3). Additionally,
memory was significantly correlated with left temporal
SH volumes in AD only (β = −0.13, R2 = 0.02, P <0.05)
(Figure 4). Overall, patients with AD demonstrated highly
significant correlations with BPF in all cognitive do-
mains examined (Executive: β = 0.26, R2 = 0.07, P <0.0001;
Mental Processing Speed: β = −0.31, R2 = 0.08, P <0.0001;
Memory: β = 0.30, R2 = 0.09, P <0.0001).
Discussion
Despite numerous clinically based research studies, the
clinical relevance of SH remains to be fully elucidated.
The most well-documented risk factors for presence of
SH are aging, hypertension, and other cerebrovascular
risk factors [36-39]. SHs have also been associatedwith cognitive decline, particularly speed of information
processing and executive functions [40-43], as well as
physical disability, particularly gait disorders and poor
motor dexterity [12,44-47]. In neuropsychological studies,
correlations with poor attention and reduced speed of
mental processing have been consistent across many series
[36,48,49].
In patients with AD, SHs have been previously corre-
lated with MMSE scores and Clinical Dementia Rating
scores, even after adjusting for potentially compounding
variables such as age, sex, and cardiovascular risk factors
[50]. Additionally, periventricular WM changes have been
reported in 48% to 100% of AD cases [51,52]. However,
when simultaneously considered with measures of GM
and WM atrophy, SHs often explain only a small pro-
portion of the variance, usually in relation to executive
function measures [13,53,54].
The main results of our study support the hypothesis
that regional signs of small vessel disease may be differen-
tially correlated with executive function, mental process-
ing speed, and memory. Whereas numerous reports from
the literature show mixed results with whole-brain SH
volumetrics and associations with cognitive functioning,
limited reports have demonstrated brain-behavior rela-
tionships with hyperintensities in specific brain regions
[6,11,40,55-60]. However, one study which examined the
Table 3 Summary of significant regression β coefficients
with subcortical hyperintensity volumetrics and cognitive
domains
β coefficient R2 P value
Atrophy, measured by BPF
AD (n = 265)
pvSH −0.14 0.02 0.02
Education, years −0.16 0.03 0.009
MMSE 0.12 0.01 0.06
NC (n = 100)
Age −0.64 0.42 <0.0001
Sex 0.16 0.04 <0.05
Atrophy, measured by vCSF
AD (n = 265)
Total SH 0.31 0.10 <0.0001
Education, years 0.14 0.02 0.02
Sex −0.12 0.02 0.04
NC (n = 100)
Age 0.49 0.24 <0.0001
Executive
AD (n = 223)
BPF 0.26 0.07 <0.0001
NC (n = 94)
Medial middle frontal SH −0.24 0.07 0.01
Education, years 0.23 0.06 <0.05
BPF 0.31 0.10 <0.01
Mental processing speed
AD (n = 222)
pvSH 0.17 0.03 0.01
Age −0.33 0.08 <0.0001
BPF −0.31 0.08 <0.0001
NC (n = 88)
Age 0.24 0.06 <0.05
Memory
AD (n = 236)
Left temporal SH −0.13 0.02 <0.05
Education, years 0.22 0.05 0.001
BPF 0.30 0.09 <0.0001
NC (n = 95)
Education, years 0.25 0.08 <0.01
Age −0.40 0.18 <0.0001
AD, patients with Alzheimer’s disease; BPF, brain parenchymal fraction; MMSE,
Mini-Mental State Exam; NC, cognitively normal elderly controls; pvSH,
periventricular subcortical hyperintensity; SH, subcortical hyperintensity; vCSF,
ventricular cerebrospinal fluid.
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strategic frontal lobe damage may modulate executive
function [61]. More specifically, patients with damage
in the medial frontal region, a region which corresponds
to the SABRE parcellated MMF region (Figure 2), were
shown to perform poorly on the FAS ‘letter-based’ verbal
fluency task [62]. Additionally, several studies examining
strategic SH on the cholinergic WM tracts have demon-
strated correlations with executive, visuospatial, and mem-
ory function [63-67]. A novel study (on a group of normal
elderly patients) using a combination of structural and
functional MRI demonstrated that an increase in SH
within the dorsolateral prefrontal cortex was associated
with decreases in prefrontal cortex activity during a work-
ing memory task [68]. Another study using FLAIR im-
aging to examine older stroke patients found differential
associations with SH, demonstrating that SH volumes in
the frontal lobe were associated with cognitive processing
speed and attention, while SH volumes in the temporal
lobe were associated with memory impairment [9]. Finally,
a recent study using a voxel-based analysis method found
specific clusters of SH to be associated with executive
function and episodic memory [7].
Although the results of our study support this handful
of studies reported in the literature, it is unclear why
more groups have not reported similar findings, given
the widespread availability of imaging techniques which
allow SH quantification.
It is likely that the limited number of reports found
in the literature is due to methodological differences
in quantification of SH as well as a lack of standardized
definitions for periventricular, deep white, and lacunar-
like, cystic fluid-filled infarcts [2,15,69,70]. Although the
increasing popularity of thinner-slice 3D FLAIR images
has allowed more automatic segmentation of SH, it has
also introduced more variability as FLAIR images have
been shown to have lower sensitivity in different brain
regions [71]. Various approaches have also been applied
for the separation of pvSH from dwSH, where some
groups have employed proportional distances from the
ventricles to the dura matter [15], whereas other groups
employ an arbitrary distance from the ventricles [72]. Our
study applied a 3D connectivity algorithm, similar to that
of van den Heuvel and colleagues [10] (2006), whose
results will clearly vary from the previously mentioned
approaches. Additionally, many older studies were based
on semi-quantitative data obtained from visual rating
scales to estimate SH load [63,73-75] or with the use
of volumetric estimates derived by adding slice-by-
slice semi-quantitative ratings with spherical shape as-
sumptions for each lesion [76]. Furthermore, a recent
meta-study examining differences in lacunar lesion defi-
nitions revealed a wide variation in the literature regarding
the detection and classification of lacunar lesions and thus
Figure 1 Partial regression plots illustrating the relationships in Alzheimer’s disease patients between atrophy measured by brain
parenchymal fraction (BPF) and periventricular subcortical hyperintensity (pvSH) volume (top), and between atrophy measured by
ventricular cerebrospinal fluid (vCSF) volume and subcortical hyperintensity (SH) volume (bottom).
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Figure 2 Regional Semi-Automatic Brain Region Extraction (SABRE) parcellation. Medial middle frontal is displayed in green on sagittal T1.
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small vessel disease [70], now achieved by the STRIVE
recommendations [2].
In a recent study examining early- and late-onset AD, a
relationship was demonstrated with frontal SH and mental
processing speed by using the Trails A score [57]. Unfor-
tunately, cross-comparisons with our study are difficult as
this study did not examine the relationship with mental
speed using the periventricular and deep white delinea-
tions. However, correlations with mental processing speed
and SH in the periventricular region have been reportedFigure 3 Segmentation of periventricular subcortical hyperintensity (
on coregistered proton density (center) and T1-weighted (right) magin at least one major longitudinal study, which demon-
strated that progression of pvSH was associated with
increased time to complete a Stroop test in a large sample
of non-demented elderly patients [10]. Although our study
was cross-sectional, a similar association was found by
using the Trails A trail-making test in a group of demen-
ted elderly patients. Interestingly, the volumetric table in
the study by van den Heuvel and colleagues [10] reports a
mean volume for pvSH at baseline of (4.12 cc), which is
comparable to the normal elderly pvSH volume in the
current study (4.5 cc).pink) and deep white subcortical hyperintensity (green) overlayed
netic resonance imaging.
Figure 4 Regional Semi-Automatic Brain Region Extraction (SABRE) parcellation. Posterior temporal lobe is displayed in blue on axial T1
(left) and three-dimensional eroded T1 (right).
Ramirez et al. Alzheimer's Research & Therapy 2014, 6:49 Page 8 of 12
http://alzres.com/content/6/4/49A possible explanation for this decrease in mental
processing speed related to pvSH has been proposed,
implicating the long association WM tracts [10,76].
Disruptions from SH in the periventricular region may
affect communication between distant multiple cortical
brain areas and may result in an overall decrease in
speed of processing. In contrast, dwSH may affect com-
munication along the so-called “U-fibers” that connect
adjacent areas of the brain and thus are less likely to
translate into a significant decrease in processing speed
[76]. In this sample, the overall volume of dwSH was
small relative to pvSH volumes in both AD and NC
(AD: pvSH = 4.5 cc, dwSH = 0.6 cc; NC: pvSH = 1.8 cc,
dwSH = 0.3).
This may suggest that the decrease in mental process-
ing speed found in patients with AD may be due in part
to some subcortical vasculopathy in the periventricular
region related to venous collagenosis [3]. Pathological
correlates suggest that pvSH may reflect a form of vaso-
genic edema resulting from venous insufficiency due to
veno-occlusive disease of the deep medullary veins in
the periventricular region, which in turn may impair
interstitial fluid circulation and exacerbate amyloid
angiopathy that is commonly associated with AD [77].
This theory is based on brain pathology imaging work that
examined the periventricular venous system in a broad
age range (25 to 95 years) of patients at autopsy [78]. The
major periventricular and subependymal veins and ve-
nules were selectively identified from arteries by using
alkaline phosphatase microvascular staining combined
with a modified Masson trichrome collagen counter-
stain. Assessment of this vasculature revealed that theperiventricular veins from 65% of subjects over 60 years
old had at least 50% stenosis of the periventricular veins
because of non-inflammatory collagenous thickening of
the venous walls. Moreover, regression analyses revealed
that greater venous disease was associated with more se-
vere leukoaraiosis, which was observed as hyperintensities
on MRI. Subsequent studies led the authors to conclude
that the thickening of the walls of periventricular veins
and venules, with collagen subtypes I and III, results in
stenosis and occlusion which may restrict venous outflow
[79]. This venous collagenosis was believed to be a
possible significant contributor to leukoaraiosis, as this
venous pathology was likely a progressive and age-related
pathology associated with increased WM signal intensity
in the periventricular region on MRI of elderly, AD, and
vascular dementia patients [80,81].
In our study, no brain-behavior relationships were
demonstrated with lacunar lesion subtypes. As stated
previously, there is a large variation in detection and
identification of lacunes, consensus-driven definitions
have yet to be established, and recent controversies in
this matter are yet to be resolved [70,82]. For clarification
purposes, lacunar volumes in the current study were
defined as any hypointense (CSF intensity) voxels on T1
that are found within hyperintense SH-defined voxels on
PD/T2. A large number of participants in our sample
population had no signs of lacunar infarction as defined
by this segmentation method. Although patients with AD
in our study had a larger volume of lacunar infarcts
compared with NC, it is likely that the wide variation
and regional distribution for lacunar lesion volumes in
both groups limited correlative power in the analysis.
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ory performance is correlated with SH volumes in the left
temporal lobe. A recent study report from a Dutch group
examining patients with AD (n = 107) found a similar
association with hyperintensities in the temporal region
and memory by using the Visual Association Test [57].
Another group used a similar region of interest-based
method examining SH volumes in a stroke population
and found an association with right temporal SH and
memory by using a numerical working memory task [9].
In contrast, a composite score was used in our study,
which was composed of several memory tests that inclu-
ded a visual reproduction task as well as a verbal memory
test. Despite these varied memory components, a cor-
relation was demonstrated with SH volume in the left
temporal lobe. Unfortunately, the SABRE VOIs for the
temporal lobes were relatively large. Future releases of
this software will include further subdivisions of the
temporal lobe.
As a final comment, it is important to note that the
regional correlations with SH volumes demonstrated in
our study were relatively small compared with the large
proportion accounted for by atrophy, as indicated by
BPF. In large longitudinal studies, such as the Alzheimer’s
Disease Neuroimaging Initiative (ADNI), vascular markers
have been shown to be associated with brain atrophy.
When the Boundary Shift Integral was used as a measure
of annualized change in brain volume, a relationship be-
tween atrophy and SH was demonstrated in pre-dementia
stage participants enrolled in ADNI [83]. However, in the
ADNI sample, this relationship was demonstrated in NC
participants but not in participants with AD or mild cog-
nitive impairment (MCI). The opposite was demonstrated
in our study, which showed SH to be associated with
atrophy measures in AD patients but not in NC. This
could be due to sample differences and the inclusion of an
MCI sample, where a larger AD sample was analyzed in
our study (Sunnybrook AD: n = 265 versus ADNI AD:
n = 146), and a larger NC and MCI sample in the
ADNI study (ADNI NC: n = 197, ADNI MCI: n = 331,
versus Sunnybrook NC: n = 100).
Ventricular expansion is another commonly used MRI-
based biomarker of atrophy [32]. Longitudinal results
from the large Cardiovascular Health Study showed sig-
nificantly greater vCSF volumes in dementia cases
compared with MCI, and MCI compared with NC [33].
Additionally, it was suggested that larger vCSF volumes in
NC at baseline may be used to indicate future dementia
progression. Future longitudinal analyses examining base-
line measures of SH and atrophy may further elucidate
the predictive cognitive outcomes of these MRI markers
of disease progression.
As our study was cross-sectional, it would be interesting
to examine volumetric change over time, particularly withSH subtypes and other brain tissue compartments, to
determine whether these changes predict progression
patterns in comparison with ADNI data sets. Future
directions will examine the inclusion of additional pa-
tient groups, including those with MCI, to further
examine the relationships between disease progression
and mixed pathologies. Diffusion tensor imaging measures
of fractional anisotropy and diffusivity and arterial
spin labeling perfusion imaging obtained in a subset
of these participants will also be added to the correlative
modeling.Conclusions
In contrast to some previous studies, this study supports
the hypothesis that regional signs of small vessel disease,
observed on MRI scans of sporadic AD patients and nor-
mal elderly individuals, may be differentially associated
with specific cognitive functions. These brain-behavior re-
lationships suggest that, while the overarching neurode-
generation and atrophy associated with AD may appear to
‘trump’ subcortical vasculopathies, these subtle, yet meas-
urable, signs of small vessel disease may have potential
clinical relevance as targets for modifying vascular risk
factors and treatment for this underlying pathology
becomes better understood.Abbreviations
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